FDA to review Arpida's NDA for iclaprim

19 October 2008

Arpida, a Swiss biopharmaceutical company that focuses on the discovery, development and commercialization of novel products for the treatment of microbial infections, has received notice from the US Food and Drug Administration that the agency's Anti-Infective Drugs Advisory Committee will discuss the New Drug Application for intravenous iclaprim in complicated skin and skin structure infections during its meeting on November 18-20.

Iclaprim is a hospital antibiotic drug candidate with potent bactericidal activity against methcillin-resistant Staphylococcus aureus and an extended range of important pathogens. Arpida has also filed marketing applications in Canada and Europe.

Paul Hadvary, head of development at Arpida, said: "we are delighted to have an opportunity to present iclaprim to leading experts in the anti-infective field and to discuss important features of our NDA with the Advisory Committee."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight